Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Government Programs

When it comes to your current risk management strategy, don't let the trees grow to the sky.

Principal and Stop Loss Specialty Practice Leader, Mercer
Senior Partner, Mercer

An analysis of annual premiums by federal poverty level.

Practice Leader, Oliver Wyman Actuarial Consulting

CMS is changing the primary care payment system. Physicians must prioritize patient-centered, value-based care to keep up.

CEO of Envision Genomics, Chair-Elect of AMGA, Vice-Chair of HHS' PTAC

Fourteen percent of physicians offer virtual visits. But a new CMS rule may make telehealth more commonplace.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Ninety-five percent of employers believe it’s important Congress preserve coverage for pre-existing conditions.

Director of Employer Research for Health and Benefits, Mercer

Insights in your inbox

Subscribe

Eric Dishman discusses NIH's most ambitious research program, the All of Us Research Program, that's collecting data on millions of Americans to advance personalized medicine.

Director, All of Us Research Program, NIH

Oliver Wyman Actuarial Consulting discusses CMS changes for 2020.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting
Senior Consultant, Oliver Wyman
Senior Consultant, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Engagement Manager, Oliver Wyman

We talk UK healthcare tech advancements and cracking brain cancer globally.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe